Navigation Links
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Date:5/30/2009

myeloma patients."

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase Ib clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the latest information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
2. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
7. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
10. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
11. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... and LONDON , Sept. 30, ... MediciGlobal Ltd. announces its major milestone: ... community which caters to patients, families and caregivers, was ... tests and evolving treatments for Alzheimer,s disease. It also ... daily postings. Alzheimer,s ranks as the leading ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014 Headquartered ... (OTC: GWPC) is a diversified company comprised of several ... of advanced technology and the proven expertise of its ... health and wellness. WholeHealth Products, line of more than ... healthcare centers, and its more than 8 retail consumer ...
(Date:9/30/2014)... N.Y. , Sept. 30, 2014  Millennium ... Millennium Medical Devices, has executed a sales, marketing ... Florida based provider of ... Accountable Care Organizations (ACOs) and hospitals through a ... serves over 10,400 active Physician Purchasing Accounts that ...
Breaking Medicine Technology:MediciGlobal's Alzheimer's Community Reaches 200,000 likes and more than half a million weekly visitors 2MediciGlobal's Alzheimer's Community Reaches 200,000 likes and more than half a million weekly visitors 3MediciGlobal's Alzheimer's Community Reaches 200,000 likes and more than half a million weekly visitors 4WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2Millennium Healthcare Secures New Sales, Marketing and Distribution Agreement 2Millennium Healthcare Secures New Sales, Marketing and Distribution Agreement 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 A group of ... to combat an epidemic that, left unchecked, could create a ... are not headed to Africa. John Rogers, the Executive Director ... North Korea to fight a disease most think mankind conquered ... some 80 years ago is on the comeback in several ...
(Date:9/30/2014)... 2014 Bifidobacteria, the primary bacteria found ... diet, and stress, so a high Bifido probiotic can ... Ultimate Flora™ Men’s Complete contains 90 Billion ... Bifidobacteria strains to support a healthy large intestine (colon) ... and 32 billion cultures from 7 Lactobacillus strains to ...
(Date:9/30/2014)... in reducing the stigma associated with seeking help for ... but more improvement is still needed, according to a ... the Defense Department and the Veterans Health Administration to ... not seek needed care for mental health problems. ... treatment as a way to reduce stigma, according to ...
(Date:9/30/2014)... September 30, 2014 Healthcare advocates, patient ... National Association of Health Advocacy Consultants (#NAHAC) fifth annual ... (#NAHAC14) to be held October 30th - Nov. 1st, ... at NAHAC14: Standards and Best Practices for the Field ... a profession, advocates have needed a set of standards ...
(Date:9/30/2014)... Healthpointe is proud to announce that ... and ankle reconstruction surgeries to assist patients with severe ... specializes in the diagnosis and treatment of sports medicine, ... also trained to perform advanced Foot and Ankle Reconstruction ... is also fluent in Spanish. , Reconstructive surgical procedures ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3
... a leader,in the development and marketing of disposable ... announced today that,BSSI has been purchased by Linden ... to Microflex(R), BSSI also owns MicroActive Corporation and,FoodHandler(R), ... leading supplier,of health and safety barrier products to ...
... and special initiatives encourage smokers to say ,I Quit, at The ... ... There,s some,ash-kicking, going on at the BODY WORLDS exhibit. Lung Cancer ... California,s,6-session Ash Kickers Quit Smoking Class and BODY WORLDS, I Quit ...
... Americans Have No Long Term Care Plans, WASHINGTON, ... long term care has on American families, the U.S. ... resolution proclaiming its,support for national Long Term Care Awareness ... one of the nation,s leading providers of,individual long term ...
... raising goal for United Way of ... ... Company,(NYSE: LLY ) chairman and chief executive officer Sidney Taurel ... Lilly,s,commitment to the agency,s 2008 fundraising campaign. For the United Way ...
... researchers find , TUESDAY, Nov. 6 (HealthDay News) -- ... of preclinical cardiovascular disease, U.S researchers report.. , Researchers ... women (who were free of cardiovascular disease at the ... intima media thickness (cIMT), a measure of the ...
... a mother with Alzheimers disease appear to be at higher risk ... according to a new study by NYU School of Medicine researchers. ... in this weeks online edition of the Proceedings of the National ... among cognitively normal people who have a father, a mother, or ...
Cached Medicine News:Health News:Microflex(R) Corporation Acquired by Linden and Edgewater 2Health News:BODY WORLDS 2 & Breathe California Pair Up for Some 'Ash Kicking' 2Health News:BODY WORLDS 2 & Breathe California Pair Up for Some 'Ash Kicking' 3Health News:Congress Proclaims Support for Long Term Care Awareness Week; Recent Poll Shows Voters Want Long Term Care Included in Presidential Candidates' Healthcare Proposals 2Health News:Congress Proclaims Support for Long Term Care Awareness Week; Recent Poll Shows Voters Want Long Term Care Included in Presidential Candidates' Healthcare Proposals 3Health News:Lilly Contributes $10.8 Million to United Way Annual Campaign 2Health News:A maternal link to Alzheimer's disease 2Health News:A maternal link to Alzheimer's disease 3
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
... Tm Bioscience introduces the Tag-It™ Cystic Fibrosis ... cystic fibrosis genotyping. With validated performance criteria, ... will provide superior mutation coverage for carrier ... to diagnosis in newborns. ,The Tag-It™ ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: